COMMUNIQUÉS West-GlobeNewswire

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
11/06/2026
BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with favorable pharmacokinetic properties SAN [...]
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
11/06/2026
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 [...]
Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the 1-for-5 reverse stock split (“ [...]
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline
11/06/2026
Financing follows a series of major milestones for Neion Bio, including the company’s emergence from stealth, execution of its first commercial agreement, and continued expansion and advancement of its development [...]
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
11/06/2026
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14 [...]
BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return
11/06/2026
ELLON, Scotland, June 11, 2026 (GLOBE NEWSWIRE) -- BrewDog , one of the U.K.’s leading and most recognizable craft beer brands, part of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is rolling pint prices back to [...]
Spinach® is the Number One Vape Brand in Canada
11/06/2026
Spinach® vapes, known for exceptional quality, bold flavor profiles and advanced hardware, continue to resonate with adult consumers across Canada TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: [...]
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in [...]
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
11/06/2026
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorder Five scientific presentations will feature preclinical and clinical data [...]
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
11/06/2026
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
11/06/2026
Completion of patient dosing in the registrational Phase 2 clinical trial for 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells Data [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
11/06/2026
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted [...]
Glow Peptide Stack Launched by Koi Peptides for Laboratory Use
11/06/2026
Cheyenne, WY, June 11, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has launched research-use-only Glow peptide stack, which combines three peptides, GHK-Cu, BPC-157, and TB-500, supplied as a [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs [...]
Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease
11/06/2026
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving [...]
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
11/06/2026
Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ). 1 HCP survey data suggests only around [...]
Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
11/06/2026
NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
11/06/2026
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, [...]

Pages